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Merkel cell polyomavirus (MCV) causes an aggres-
sive human skin cancer, Merkel cell carcinoma,
through expression of small T (sT) and large T (LT)
viral oncoproteins. MCV sT is also required for effi-
cient MCV DNA replication by the multifunctional
MCV LT helicase protein. We find that LT is targeted
for proteasomal degradation by the cellular SCFFbw7
E3 ligase, which can be inhibited by sT through its
LT-stabilization domain (LSD). Consequently, sT
also stabilizes cellular SCFFbw7 targets, including
the cell-cycle regulators c-Mycandcyclin E.Mutating
the sT LSD decreases LT protein levels and elimi-
nates synergism in MCV DNA replication as well as
sT-induced cell transformation. SCFFbw7 knockdown
mimics sT-mediated stabilization of LT, but this
knockdown is insufficient to fully reconstitute the
transforming activity of a mutant LSD sT protein.
Thus,MCV has evolved a regulatory system involving
SCFFbw7 that controls viral replication but also con-
tributes to host cell transformation.
INTRODUCTION
Merkel cell carcinoma (MCC) is one of the most aggressive
human skin cancers, with a mortality rate exceeding melanoma
(Lemos and Nghiem, 2007) and a tripled incidence between
1986 and 2001 (Hodgson, 2005). Approximately 80% of MCCs
are caused by the newly discovered Merkel cell polyomavirus
(MCV) (Feng et al., 2008), a small DNA virus that is an asymptom-
atic component of normal human skin flora (Tolstov et al., 2011).
MCV-MCC tumors arise when the virus integrates into the host
cell genome, and mutations occur that inactivate the DNA-bind-
ing/helicase functions of MCV large T (LT) (Shuda et al., 2008).
Xenomutation to commensal flora such asMCV is an unexpected
mechanism for human carcinogenesis (Arora et al., 2012).
Similar to other polyomaviruses, MCV LT and small T (sT) early
antigens act in natural infections to promote virus replication.
However, the expression of a replication-defective, C-terminally
truncated MCV LT antigen promotes tumorigenesis in humanCell HosMerkel cells. Both LT and sT antigens are required for MCV-pos-
itive MCC cell survival and proliferation (Houben et al., 2010,
2012; Shuda et al., 2011). In in vitro cell transformation assays,
MCV sT is sufficient to transform rodent fibroblasts in culture,
whereas MCV LT cannot (Shuda et al., 2011). This is in marked
contrast to the more well-known polyomavirus SV40, in which
SV40 LT is the major transforming oncoprotein, whereas sT
promotes cell transformation (Hahn et al., 2002) but is not fully
transforming on its own (Bikel et al., 1987).
A comparison of the cellular targets of SV40 and MCV viral sT
proteins shows similarities as well as differences. Both MCV and
SV40 sT target protein phosphatase 2A (PP2A) and heat-
shocked proteins through direct protein-protein interactions.
SV40 sT prevents PP2A dephosphorylation of Akt, whereas
MCV sT has minimal effect at this node of the Akt-mTOR
signaling pathway (Shuda et al., 2011). MCV sT, instead, acts
downstream ofmTOR to increase levels of hyperphosphorylated
4E-BP1, a regulator of cap-dependent translation. MCV
sT-induced cell transformation is independent of PP2A binding
but can be inhibited by a constitutively active mutant 4E-BP1
protein. In contrast, SV40 sT has been reported to diminish
4E-BP1 phosphorylation (Yu et al., 2005).
MCV sT also plays a key role in promoting MCV genome repli-
cation. MCV LT assembles on a 71 bp stretch of the viral replica-
tion origin by recognizing specific pentanucleotide sequence
repeats (Harrison et al., 2011; Kwun et al., 2009). For SV40, sT
coexpression has minimal effect on SV40 LT-mediated replica-
tion. However, for MCV (Kwun et al., 2009) and JC polyomavirus
(Prins and Frisque, 2001), sT coexpression markedly enhances
LT-mediated viral DNA synthesis, although the mechanism for
this effect is unknown. Like papillomaviruses, MCV is poorly
transmissible in culture. Replication of genomic MCV clones
(Feng et al., 2011; Neumann et al., 2011; Schowalter et al.,
2011) can be markedly enhanced by coexpression of an MCV
sT from a heterologous promoter (Feng et al., 2011).
While investigating themechanism bywhichMCV sT synergis-
tically enhances MCV LT-dependent replication, we found that
MCV sT targets the cellular SCF (complex of Skp1, Cul1, and
F box protein) ubiquitin ligase protein complex, SCFFbw7. Fbw7
(F box and WD repeat domain-containing 7, also known as
FBXW7, CDC4, AGO, and SEL10) serves as the substrate
recognition component for this multiprotein cullin-RING ubiq-
uitin ligase complex that includes Fbw7, Skp1, Cul1, and Rbx1
(Welcker and Clurman, 2008). The importance of Fbw7 int & Microbe 14, 125–135, August 14, 2013 ª2013 Elsevier Inc. 125
Cell Host & Microbe
SCFFbw7 Complex Targeting by MCV sTcontrolling cancer cell outgrowth has been highlighted by
studies showing it to be dysregulated in breast cancer, colon
cancer, and T cell acute lymphoblastic leukemia (Maser et al.,
2007; Wood et al., 2007). Numerous cancer-associated muta-
tions of FBW7 also have been reported in various cancers
(Akhoondi et al., 2007), and the loss of Fbw7 function results in
tumorigenesis and genetic instability (Mao et al., 2004; Rajago-
palan et al., 2004; Rajagopalan and Lengauer, 2004). Fbw7
recognition promotes phosphorylation-dependent degradation
in many proto-oncogenes, including cyclin E (Koepp et al.,
2001; Strohmaier et al., 2001), c-Myc (Welcker et al., 2004;
Yada et al., 2004), c-Jun (Nateri et al., 2004), Notch (Gupta-Rossi
et al., 2001; Oberg et al., 2001; Wu et al., 2001), mTOR (Mao
et al., 2008), MCL-1 (Inuzuka et al., 2011; Wertz et al., 2011),
and NF-kB2 (p100/p52) (Arabi et al., 2012; Fukushima et al.,
2012), indicating that Fbw7 is a critical nexus for diverse
signaling pathways regulating cell proliferation and tumor
suppression.
We show here that MCV LT oncoprotein level is regulated by
Fbw7. MCV sT, through inhibition of Fbw7, enhances MCV
genome replication by promoting accumulation of the MCV LT
oncoprotein. This targeting of SCFFbw7 is mediated through an
LT-stabilization domain (LSD) that maps to residues 91–95 and
is predicted to be on the opposite molecular face of sT from its
PP2A-targeting site. Mutation of the LSD not only abolishes
MCV sT stabilization of MCV LT but also eliminates sT-induced
rodent cell transformation, inhibits viral replication, and prevents
MCV sT induction of several cellular oncoproteins, including
c-Myc and cyclin E. These effects are independent of MCV sT
binding to PP2A. In MCC tumor cells, having defective MCV
genomes incapable of replication, MCV sT stabilizes and
increases steady-state levels of viral and cellular oncoproteins.
Fbw7 knockdown alone does not rescue the transforming
phenotype for the MCV sT LSD mutant protein, however, sug-
gesting that the LSD-targeting domain also affects a broader
range of cell signaling pathways.
RESULTS
MCV sT Enhances LT-Mediated MCV Origin Replication
through a PP2A-Independent Mechanism
Using an MCV origin replication assay (Kwun et al., 2009), we
tested various MCV sT constructs for their effect on MCV
LT-dependent origin replication activity (Figure 1). Separate sT
constructs and full-length, wild-type (WT)MCV LT (or empty vec-
tor) plasmids were cotransfected into 293 cells together with
a plasmid containing the MCV replication origin (Ori339(97))
(Kwun et al., 2009). No replication of the origin plasmid occurs
in the absence of MCV LT (Figure 1A, lane 1). Expression of
MCV LT (Figure 1A, lane 2) activates baseline origin plasmid
replication, which is amplified 5-fold by cotransfection of WT
MCV sT (Figure 1A, lane 3). This enhancement of MCV LT repli-
cation by sT is largely unaffected whenWTMCV sT expression is
substituted with expression of mutant MCV sT having alanine
substitutions in amino acids (aa) R7 or L142 (Figure 1A, lanes 4
and 5) that inhibit PP2A interaction (Shuda et al., 2011) or an
aspartate-asparagine substitution at D44 (Figure 1A, lane 6) in
the MCV sT DnaJ domain eliminating heat-shocked protein
(Hsc70) interactions (Kwun et al., 2009).126 Cell Host & Microbe 14, 125–135, August 14, 2013 ª2013 ElseviMCV sT is generated by readthrough of the splice-donor site in
Exon 1 (aa 1–79) to produce a unique sT C terminus peptide en-
coded by Exon 1A (aa 80–186) (Figure 1A) (Shuda et al., 2008,
2009). SV40 sT is similarly generated from an 82 aa Exon 1,
which reads through splice site to generate a C-terminal region
(aa 83–174). MCV sT and SV40 sT proteins are highly homolo-
gous to each other (33% aa identity by the BLAST program). In
contrast to MCV sT, SV40 sT does not cross-enhance MCV
LT-mediated DNA replication despite conserved PP2A and
Hsc domains (Figure 1A, lane 7). However, a chimeric sT
comprised of SV40 sT Exon 1 (aa 1–82) and MCV Exon 1A
(aa 80–186)-designated SV40/MCV sT (Figure 1A, lane 8)
restored DNA replication activation, suggesting that the respon-
sible domain is encoded in the MCV sT C terminus. The reverse
chimeric construct (MCV/SV40 sT) comprised of N terminus
MCV Exon 1 (aa 1–79) and C terminus SV40 Exon 1A (aa 83–
174) could not be evaluated due to protein instability. Notably,
MCV sT constructs that activated MCV origin replication also
correlatively enhanced levels of MCV LT protein expressed
from a heterologous promoter (pcDNA6). SV40 sT, which
increased MCV LT protein expression, did not enhance MCV
DNA replication (Figure 1A, lane 7). In line with our observation
that MCV sT affects MCV LT protein levels, increased LT
expression was consistently detected in populations of cells
coexpressing sT but not in cells expressing only LT by immuno-
fluorescence (Figure S1 available online).
To map the MCV sT domain that enhances LT-dependent
MCV DNA replication, we constructed sT mutants with sequen-
tial 5 aa deletions or five alanine substitutions in its C-terminal
Exon 1A. Deletion at residues 91–95 (sT.91–95D, Figure 1B,
lane 5), as well as alanine substitution (sT.91–95A, Figure 1B,
lane 6), ablated enhanced MCV DNA replication and reduced
LT protein levels. Enhanced replication was also diminished
compared to the WT sT protein (Figure 1B, lane 2) by deletion
of residues 86–90 (sT.86–90D) (Figure 1B, lane 3). This, however,
likely results from reduced stability of the mutant sT protein
because that steady-state sT.86–90D protein level is reduced
compared toWT sT. Alanine substitutions at aa 86–90 (Figure 1B,
lane 4) fully restored this mutant’s protein stability and activation
of MCV LT-mediated replication.
The high homology between MCV sT and SV40 sT allowed us
to model MCV sT (I-TASSER) by threading its sequence onto the
SV40 sT crystal structure (Protein Data Bank ID codes [PDBs]
2PF4 and 2PKG) (Chen et al., 2007; Cho et al., 2007). This pre-
dicts that the MCV sT aa 91–95 region, designated the LSD,
forms a larger loop structure than the one present in the SV40
sT molecule (Figure 2; Movie S1). The LSD is predicted to be
on the opposing surface of the MCV sT from the PP2A-inter-
action region and distinct from the DnaJ domain (Movie S1),
correlating with the mutation analysis in Figure 1A.
MCV sT Synergistically Enhances MCV LT-Dependent
Virus Replication
We next sought to determine if increased MCV LT protein accu-
mulation by MCV sT contributes to MCV replication. Cotransfec-
tion of small amounts of WT sT expression plasmid (0.1 mg)
maximally activated LT expression (Figure 3A) and LT-depen-
dent origin replication (Figure S2A). This is not due to enhanced
transcription of the LT gene because sT does not increase LTer Inc.
Figure 1. MCV sT Enhances LT-Mediated MCV Origin Replication through an Exon 1A Domain in a PP2A-Independent Manner
(A) AnMCV sT Exon 1A-encoded domain enhancesMCV LT-dependent origin replication. DiagramcomparesMCV andSV40 sT-coding regions and sites ofMCV
point mutations used in replication assay. SV40 Exon 1A (83–174 aa) was replaced with MCV Exon 1A (80–186 aa) to make the chimeric construct, SV40/MCVsT.
The obverse MCV Exon 1 and SV40 Exon 1A chimeric (MCV/SV40sT) could not be evaluated due to its protein instability. DpnI-resistant MCV origin replication in
293 cells was assayed by Southern blotting (middle panel) in the absence of T antigens (lane 1), in the presence of LT alone (lane 2), or LT together with MCV or
SV40 sT proteins (lanes 3–8). MCV sT point mutants that eliminate PP2A binding (lanes 4 and 5) and Hsc70 binding (lane 6) have comparable activity to theWT sT
protein (lane 3). SV40 sT did not induce enhanced LT-dependent MCV origin replication (lane 7), but the SV40/MCV sT chimeric protein possessing the C-terminal
MCV peptide sequence (lane 8) restored origin replication activity. Corresponding immunoblots for LT (CM2B4) and sT proteins (mixture of anti-MCV sT [CM8E6]
and anti-SV40 LT/sT [pAb419]) are shown (lower panels).
(B) Identification of an MCV sT LSD responsible for enhanced LT-mediated origin replication. MCV origin replication was assayed in 293 cells by coexpression of
LT together with sTmutants having sequential 5 aa deletions or five alanine substitutions in Exon 1A from 86 to 104 aa. Deletion or substitution atMCV sT aa 91–95
(LKDYM) ablated enhanced origin replication and increased steady-state MCV LT protein expression (lanes 5 and 6) compared to WT MCV sT (lane 2). Deletion
(but not alanine substitutions) at residues 86–90 reduced sT protein stability as well as origin replication and LT expression. See also Figure S1.
Cell Host & Microbe
SCFFbw7 Complex Targeting by MCV sTmRNA levels (Figure 3B). These effects can be demonstrated
with whole-MCV genome replication as well. MCV sT expressed
in trans markedly activates viral replication from the MCV-HF
plasmid clone (Figure 3C) (Feng et al., 2011). The effect is lost
using MCV sT having alanine substitutions in the LSD (MCV
sT.LSD91–95A). In the MCV-positive MCC cell line MKL-2, knock-
down of MCV sT was correlated with reduction in LT protein
expression (Figure S2B).
MCV sT Inhibits Proteasomal Degradation of MCV LT
To measure sT effects on LT stability, quantitative immunoblot-
ting (Figures 3D and S2C) was used to measure LT abundance
in the presence of the translation inhibitor cycloheximide
(CHX). In the absence of sT, LT had a rapid turnover with a
half-life (t1/2) of 3–4 hr and diminished to low levels within
24 hr after CHX addition. Coexpression of sT together with LT
increased the t1/2 for LT to >24 hr but did not significantly alter
the stability of a control protein (EGFP). Additional evidence
that sT inhibits LT turnover was seen after treatment with the
proteasome inhibitor MG132 (Figure 3E). MG132 treatment didCell Hosnot increase LT levels above those found with sT coexpression
alone (Figure 3E, lanes 5 and 6), consistent with both sT and
MG132 acting to prevent LT proteolysis. In this same experi-
ment, WT sT expression led to accumulation of LT protein after
24 hr of 0.1 mg/ml CHX treatment (Figure 3E, lanes 8 and 9),
which was not seen during expression of sT.LSD91–95A
(Figure 3E, lane 10). MG132 markedly increases sT and
sT.LSD91–95A levels (Figure 3E, lanes 6 and 7), indicating that
sT itself is subject to rapid proteasomal turnover.
SCFFbw7 Binds to and Promotes Turnover of MCV LT
SV40 LT is a pseudosubstrate for Fbw7 (Welcker and Clurman,
2005), and so we examined potential interaction between MCV
LT and Fbw7 by immunoprecipitation (IP) (Figures 4A and 4C).
When MCV LT (Figure 4A) or sT (Figure 4B) is expressed in
U2OS cells, specific coIP with HA-Fbw7 was readily detectable
with each viral protein. For sT, mutation within the LSD elimi-
nated the sT-Fbw7 interaction. MCV LT, however, is a polyphos-
phoprotein with multiple potential consensus F box-binding
motifs (S/TPXX) that could serve as recognition sequences fort & Microbe 14, 125–135, August 14, 2013 ª2013 Elsevier Inc. 127
Figure 2. Predicted Model of MCV sT
Structure
MCV sT protein structure based on the SV40 sT
crystal structure (I-TASSER server) shown in both
space-filling and ribbon representations. The latter
reveals the conserved structures with overlapping
regions for SV40 (green) and MCV (turquoise).
PP2A binding (gold) and DnaJ (magenta) domains
conserved for both viruses are shown. The MCV
LSD (red underline) is in a large unstructured loop
(red) on the opposite molecular face from the
PP2A-binding domain that is foreshortened in
SV40 (black). Amino acid alignment between MCV
sT and SV40 sT (32.52% sequence identity) in-
dicates (j) identical, (:) similar, and (.) dissimilar
residues and shows loss of homology in the region
corresponding to the LSD. See also Movie S1.
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site(s) on LT are ongoing and are complicated by multiple phos-
phorylation-dependent turnover pathways for the LT protein
(data not shown), but preliminary analyses suggest that this
domain is likely to be conserved in most tumor-derived MCV
strains. In 293 cells, Fbw7 was rapidly turned over and required
MG132 treatment for robust detection. Consistent with this, LT
and sT interaction with Fbw7 was only revealed in the presence
of MG132 (Figures 4C and 4D).
Fbw7 targeting of MCV LT is inhibited by coincident expres-
sion of MCV sT protein as shown in Figure 4E. 293 cells ex-
pressing HA-tagged Fbw7 were treated with MG132 and then
immunoprecipitated using a HA-tagged antibody. LT immuno-
precipitated with HA-Fbw7 (Figure 4E, lane 5), but this interaction
is markedly diminished by expression of sT together with LT (Fig-
ure 4E, lane 6), which can be reversed by mutation to the sT LSD
(Figure 4E, lane 7). Fbw7 IP of c-Myc protein (Yada et al., 2004)
was performed as an IP control (Figure 4E, lane 4). In addition, an
arginine mutant of human Fbw7 R465C, which is defective in
binding to its substrate (Akhoondi et al., 2007), was examined
for LT binding. MCV LT interacts with WT Fbw7, but it loses its
binding with R465C mutant (Figure S3).
To examine whether the ubiquitylation status of LT is Fbw7
dependent, LT and a vector containing CMV promoter-driven
HA ubiquitin were cotransfected in HCT116 WT and Fbw7(/)
cells. IP of LT followed by immunoblot analysis of the HA ubiqui-
tin showed efficient LT ubiquitylation found in cells preserving a
functional Fbw7 gene and reduced ubiquitylation in Fbw7(/)
cells (Figure S4A). Ubiquitylation of LT is also reduced by sT
overexpression. Proteasome inhibition using MG132 increased128 Cell Host & Microbe 14, 125–135, August 14, 2013 ª2013 Elsevier Inc.the amount of ubiquitin chains bound to
LT and is reduced by sT, suggesting
that MCV sT inhibits LT ubiquitylation by
prohibition of Fbw7 E3 ligase activity.
Consistent with sT targeting Fbw7 to
enhance steady-state LT expression,
knockdown of cellular Fbw7 by lentiviral
transduction also decreased turnover
rates of LT protein (Figure 5A). In these
experiments, we were unable to measure
endogenous Fbw7 levels using commer-cial antibodies, and so knockdown efficacy was monitored by
ectopic HA-Fbw7 expression. Whole-virus replication was also
enhanced by Fbw7 knockdown (Figure 5B). Cells transduced
by scrambled (Scr) or shFbw7 lentiviruses were transfected
with MCV-HF genome, and MCV replication was assessed.
Fbw7 knockdown alone enhanced virally expressed LT protein
and VP1 protein expression and virus genome replication. Coex-
pression of sT protein (Figure 5B, lane 4)markedly increased viral
replication that was further increased by simultaneous knock-
down of Fbw7 (Figure 5B, lane 8). In comparison, MCV-Rep
(Figure 5B, lanes 2 and 6) is a replication-defective control virus
having a point mutation in its replication origin (Feng et al., 2011).
As expected, MCV-Rep showed no late protein or genome
replication after Fbw7 knockdown, but knockdown did increase
MCV-Rep LT protein levels, indicating that this effect was not
dependent on virus replication.
These Fbw7 knockdown results were confirmed using
HCT116 cells engineered for deletion of the FBW7 gene (Rajago-
palan et al., 2004). Transient LT protein was barely detected in
homozygous Fbw7 WT(+/+) cells but increased 10-fold when
the same amount of LT DNA was transfected into homo-
zygous(/) Fbw7 null cells (Figure 5C). Intermediate LT protein
levels were detected in cells with hemizygous(+/) Fbw7 status.
Similarly, LT expression from the MCV-HF virus was minimal in
WT HCT116 cells but markedly increased in Fbw7 null HCT116
cells (Figure 5D). MG132 proteasome inhibition increased LT
expression from virus in WT but not in Fbw7 null HCT116 cells.
The effect of sT expression on the cellular Fbw7 oncoprotein
target c-Myc was examined in Rat-1 fibroblasts transduced
with empty vector, sT or sT.LSD91–95A, sT.L142A, and SV40
Figure 3. MCV sT Inhibits Proteasomal Degradation of MCV LT
(A) MCV sT expression increases LT expression through a domain encompassed by aa 91–95. Extremely low levels of sT.WT expression (0.1 mg transfected
plasmid) results in fully saturated (five to seven folds) LT stability. In contrast, the titration of mutant (sT.LSD91–95A) expression, even over a broad range of levels,
has no effect on LT stability. Quantitative LI-COR Biosciences immunoblotting for LT expression was determined using CM2B4 antibody in triplicate, with a
representative shown.
(B) MCV sT expression does not transcriptionally regulate MCV LT expression. 293 cells were transfected with empty vector (lane 1, negative control), sT alone
(lane 2), LT alone (lane 3), LT and sT together (lane 4), and quantitative RT-PCR was performed to detect LT mRNA transcription. Corresponding levels of sT and
LT protein expression by immunoblotting are shown. Error bars represent SEM (n = 3).
(C) sT expression in trans increases MCV replication. MCV-HF (0.3 mg) was cotransfected with empty vector (lane 2), sT WT (lane 3), sT.LSD91–95A mutant (lane 4)
(0.3 mg each) into 293 cells, and replication was assayed by Southern blotting. WTMCV sT cotransfection markedly activates viral replication (upper panel) and LT
expression (lower panel) from the MCV-HF clone, whereas the MCV sT LSD mutant does not.
(D) MCV sT specifically inhibits LT protein turnover. LT protein turnover was measured by a CHX chase assay using quantitative immunoblot analysis. LT (0.3 mg)
and EGFP (0.3 mg) constructs were cotransfected together with either empty vector or sT plasmid (0.3 mg). Cells were treated with CHX (0.1 mg/ml) 24 hr after
transfection and harvested at each time point indicated. Protein expression was quantified in triplicate using a LI-COR Biosciences IR imaging system (bottom).
Coexpression of sT extended the t1/2 of LT from 3–4 hr up to >24 hr but did not significantly affect EGFP turnover. Error bars represent SEM (n = 3).
(E) MCV sT inhibits proteasomal degradation of LT protein. 293 cells were transfected with LT with either WT sT or sT.LSD91–95A. Cells were treated with MG132
(10 mM) or CHX (0.1 mg/ml) 24 hr after transfection. Comparable levels of LT accumulation are seen with empty vector or sT.LSD91–95A expression to those seen
with WT sT expression during MG132 treatment. See also Figure S2.
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Both sT and sT.L142A increased c-Myc expression and pro-
longed its turnover, an effect that is lost for sT.LSD91–95A. Cyclin
D1, a target of SCFSkp2, SCFFbx4, and SCFFbw8 (Lin et al., 2006;
Okabe et al., 2006; Yu et al., 1998), was unaffected by sT ex-
pression. Overexpressed HA-Fbw7 increased turnover of Flag-
labeled c-Myc in 293 cells, and this could be fully reversed by
simultaneous expression of MCV sT (Figure 5F). Cyclin E turn-
over is also reduced by sT but not sT.LSD91–95A expression (Fig-
ure S4B). MCV sT activates 4E-BP1 hyperphosphorylation
required for MCV sT-induced transformation (Shuda et al.,
2011), but unlike c-Myc, we did not find evidence that 4E-BP1Cell Hosis regulated by Fbw7 (Figure S4C), suggesting that sT effects
on 4E-BP1 hyperphosphorylation are independent of Fbw7
targeting.
The sT LSD Is Required for sT-Induced, PP2A-
Independent Rat-1 Cell Transformation
Focus formation and soft agar colony growth assays were used
to determine cell transformation of Rat-1 (Figure 6A) and NIH
3T3 cells (Figure S5) after lentiviral transduction with various
sT genes (Shuda et al., 2011). Only WT MCV sT and
sT.L142A reproducibly formed colonies after 3 weeks of growth
in soft agar. In contrast, the MCV sT.LSD91–95A mutationt & Microbe 14, 125–135, August 14, 2013 ª2013 Elsevier Inc. 129
Figure 4. sT Targets SCFFbw7 Complex to Stabilize LT
(A) LT interacts with the Fbw7 E3 ligase complex. HA-tagged Fbw7 (6 mg) was cotransfected with MCV LT (6 mg) into U2OS cells and immunoprecipitated with
anti-HA antibody. LT interaction was detected with CM2B4 antibody. Negative controls for IP include transfection with LT alone or an empty vector. IB,
immunoblotting.
(B) sT interacts with the Fbw7 E3 ligase complex. HA-Fbw7 (6 mg) was cotransfected withWT (sT.WT) or mutant (sT.LSD91–95A) or empty vector (6 mg), followed by
HA IP and immunoblotting for sT using CM8E6 antibody. MCV sT, but not mutant sT (sT.LSD91–95A), interacted with overexpressed HA-Fbw7. White arrowhead
indicates immunoglobulin light chains (LC) at 25 kDa.
(C) LT interaction with the Fbw7 E3 ligase complex is accentuated with MG132 treatment. Binding of MCV LT to Fbw7 was examined with lysates treated with
MG132 (10 mM, 24 hr). Both MCV LT and Fbw7 proteins are stabilized in 293 cells treated with MG132, and protein interactions are more readily detected as
compared to vehicle treatment control.
(D) sT interaction with the Fbw7 E3 ligase complex is also revealed with MG132 treatment. Fbw7 was cotransfected into 293 cells with WT (sT.WT) or mutant sT
(sT.LSD91–95A) or empty vector. Cells were treated with MG132 (10 mM) 24 hr after transfection, then harvested. CM8E6 was used for sT IP followed by Fbw7
detection using HA antibody. Fbw7 in cell lysates as well as following IP with sT is more readily detectable by MG132 treatment.
(E) MCV sT inhibits Fbw7 interaction with MCV LT. LT, sT, Flag-c-Myc, and HA-Fbw7 proteins were expressed in 293 cells treated with MG132 (10 mM) for 24 hr.
Cell lysates were then immunoprecipitated with anti-HA antibody and immunoblotted for LT or Flag-c-Myc. No IP is seen in negative control lanes transfected
with HA-expressing vector without Fbw7 (lanes 1–3), but coIP of Flag-tagged c-Myc (lane 4) and LT (lane 5) by HA-Fbw7 is evident. LT-Fbw7 interaction is
inhibited when both LT and sT are coexpressed with HA-Fbw7 (lane 6), but not when LT is coexpressed with the LSD mutant (lane 7). White arrowhead indicates
the immunoglobulin heavy chains (HC) at 50 kDa. See also Figure S3.
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activity, as previously described (Chang et al., 1984). These
differences occur in the setting of comparable levels of sT
expression for the different constructs (Figure 6B). As seen in
Figure 6C, the sT.LSD91–95A mutation did not affect sT binding
to endogenous PP2Ac in Rat-1 cells, whereas the sT.L142A
mutation eliminated PP2Ac interaction reaffirming that MCV
sT transforms cells through a PP2A-independent mechanism
(Shuda et al., 2011). We did not, however, find that SCFFbw7
targeting by MCV sT is sufficient to transform cells, and LSD
mutant sT protein was not complemented by lentiviral knock-
down of Fbw7 protein (Figure S6) in rodent cell transformation
(Figure 7).
DISCUSSION
MCV sT is a viral oncoprotein that causes cell transformation as
measured by focus formation assays and anchorage-indepen-130 Cell Host & Microbe 14, 125–135, August 14, 2013 ª2013 Elsevident growth of NIH 3T3 and Rat-1 cells. This effect is indepen-
dent of MCV LT (Shuda et al., 2011). MCV sT also enhances
MCV LT replication functions (Feng et al., 2011; Kwun et al.,
2009; Schowalter et al., 2011). We show here that MCV achieves
this by targeting the SCFFbw7 holoenzyme through the LSD
encoded by sT Exon 1A.
We have previously shown that sT induces hyperphosphory-
lated 4E-BP1, a regulator of cap-dependent translation, during
transformation (Shuda et al., 2011). This is not dependent on
Fbw7 targeting by sT (Figure S4C), and so the relationship
between these two sT-regulated transformation pathways
remains unclear. Fbw7 knockdown alone fails to transform
Rat-1 cells expressing sT.LSD91–95A, and so it is likely that LSD
targeting has broader effects than inhibition of SCFFbw7 alone.
Furthermore, a survey of other known cellular Fbw7 targets
such as Mcl-1 (data not shown) did not reveal consistent turn-
over inhibition, making it likely that the role of sT in transformation
is more complex than Fbw7 targeting alone.er Inc.
Figure 5. SCFFbw7 Inhibits MCV Replication and Increases Turnover of Viral and Cellular Oncoproteins
(A) Knockdown of Fbw7 reduces LT protein turnover. HA-Fbw7 and LTwere cotransfected together with either scrambled shRNA (Scr) or Fbw7 shRNA (shFbw7.2)
constructs into 293 cells. Three days after transfection, cells were treated with CHX, and LT and Fbw7 protein expressions were measured by immunoblotting.
(B) Knockdown of Fbw7 promotes MCV replication and protein expression. MCV genomic clone early and late protein expression (top panels) and genome copy
number (bottom panel) are increased in 293 cells transduced with Fbw7 shRNA compared to Scr shRNA. MCV-Rep is a replication-defective clone of MCV-HF
having a point mutation in its replication origin. Each cell line was mock transfected or transfected with a genomic clone for 5 days prior to harvesting. In lanes 4
and 8, an sT expression vector was cotransfected in trans with MCV-HF. Replication efficiency was measured in triplicate by qPCR.
(C) Genetic deletion of Fbw7 increases ectopic LT expression in HCT116 cells. LT expression was examined by immunoblotting with CM2B4 antibody in HCT116
cells null(/), heterozygous(+/), or WT(+/+) for the FBW7 gene. Quantification was performed with Image Studio software from LI-COR.
(D) Knockout of Fbw7 decreases proteasomal degradation of MCV LT from MCV-HF virus. MCV-HF was transfected into HCT116 WT and Fbw7 null cells. Five
days after transfection, cells were treated with MG132 or DMSO for 12 hr, and LT protein levels were measured by immunoblotting. In WT cells, virus-generated
LT protein was increased by proteasome inhibition. In Fbw7 null cells, LT protein expression was elevated and unchanged by MG132 treatment.
(E) sT stabilizes a proto-oncogene c-Myc but not cyclin D1 in Rat-1 cells. Rat-1 cells were stably transduced with vector, WT sT, sT.LSD91–95A, L142A, and
SV40 sT, and turnover of c-Myc and cyclin D1 was measured by CHX treatment. c-Myc protein was stabilized by either MCV sT.WT or sT.L142A, but not by
sT.LSD91–95A or SV40 sT. MCV sT did not affect turnover of cyclin D1. Mixture of CM8E6 and pAb419 antibodies was used to detect viral sTs.
(F) sT decreases the degradation rate of c-Myc. Flag-c-Myc expression construct was cotransfected with either empty vector or HA-Fbw7, with or without sT, and
turnover was measured in a CHX chase assay. Fbw7 overexpression destabilized exogenous c-Myc protein, and this was reversed by coexpression of MCV sT.
Error bars represent SEM (n = 3). See also Figure S4.
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SCFFbw7 Complex Targeting by MCV sTThe LT phosphorylation sites that serve as recognition motifs
for SCFFbw7 have not yet been mapped but seem to be retained
inmany of the tumor-derived LT proteins (data not shown). Phys-
iological substrates of Fbw7 hold the phosphodegron with a
wide range of binding affinities and retain multiple low-affinity
degrons in some case, for example, Sic1 (Nash et al., 2001),
which may allow fine-tuning of protein proteolysis. Comparing
c-Myc, MCV LT binding to Fbw7 is predicted to be weak andCell Hoslow affinitive, presumably with multiple binding sites (Figure 4).
Dimerization of Fbw7 is known to be required for the turnover
of low-affinity substrates, possibly facilitating the degradation
by multirecruitment of E2 ubiquitin conjugase (Welcker and Clur-
man, 2007), which might be the case in LT degradation. Given
the large number of potential phosphorylation sites present in
LT, degradation might be triggered by multisite sequential phos-
phorylation events to induce binding to the SCF ubiquitin ligaset & Microbe 14, 125–135, August 14, 2013 ª2013 Elsevier Inc. 131
Figure 6. MCV sT Antigen Exon 1A LSD Is Required for sT-Induced Transformation in a PP2A-Independent Manner
(A) LSD is critical for sT-induced transformation. Rat-1 cells were stably transduced with vector, WT sT, mutants (sT.LSD91–95A, L142A), and SV40 sT. Both WT
MCV sT and sT.L142A reproducibly formed colonies after 3 weeks of growth in soft agar, whereas the MCV sT.LSD91–95A mutation ablated transforming activity.
Cells were stained with crystal violet (upper). Transformation-associated foci were photographed (340) (middle), and colony number per high-power field was
counted (bottom). All assays were performed in triplicate. Error bars represent SEM (n = 3).
(B) All sT constructs show similar levels of expression in Rat-1 cell lines from transformation assays. Stable sT-expressing cell lines used for soft agar assay were
tested by immunoblotting with mixed antibodies: CM8E6 and pAb419 for MCV and SV40 sT detection, respectively.
(C) LSD mutation does not affect sT binding to PP2A. IP analysis was performed to measure PP2A-binding capacity of sT mutants stably expressed in Rat-1.
Either MCV sT antibody (CM8E6) or SV40 sT antibody (pAb419) was used for IP of sT, and endogenous PP2A was detected. The nontransforming LSDmutant sT
interacts with PP2A, similar to WT sT. A PP2A-binding mutant L142A ablates its binding to PP2A but retains its transforming activity (A). These data indicate that
the sT-transforming activity is PP2A independent. SV40 sT was used as a positive control of PP2A binding and a negative control for the transformation. See also
Figure S5.
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SCFFbw7 Complex Targeting by MCV sTcomplex, SCFFbw7. Both MCV LT and sT interact with Fbw7, but
we cannot exclude the possibility that this might be a bridging
effect mediated by direct sT targeting of other SCF complex pro-
teins (e.g., Skp1, Cul-1, or Rbx-1) or an indirect inhibitory effect
by sT on the recruitment of Fbw7 dimers to LT. Furthermore, it is
possible that LT not only has complex interaction with Fbw7 but
is also regulated by other E3 ligases affected by sT: LT is ubiqui-
tylated in Fbw7(/) cells, and sT inhibits the ubiquitylation of LT
in Fbw7(/) cells (Figure S4A). Although LT is degraded as a132 Cell Host & Microbe 14, 125–135, August 14, 2013 ª2013 Elsevitarget of SCFFbw7, sT readily interacts with Fbw7 through its
LSD without itself being targeted by Fbw7 at this site.
MCV hijacking of the SCFFbw7 circuitry nonetheless has impor-
tant consequences because this may increase expression of
viral LT as well as other cellular oncoproteins such as c-Myc
and cyclin E. The reasons whyMCV has evolved such a complex
mechanism to autoregulate LT levels through SCFFbw7 targeting
remain enigmatic. sT is an alternatively spliced isoform from LT
and is expected to be expressed together with LT under moster Inc.
Figure 7. Fbw7 Knockdown Is Insufficient for MCV sT-Induced Transformation
Rat-1 cells were stably transduced with two lentiviral shRNAs (shFbw7.1 and shFbw7.2) targeting the rat-specific Fbw7. Empty vector lentivirus, sT.LSD91–95A, or
WT MCV sT (sT.WT) was individually transduced into Fbw7 knockdown cells and subjected to transformation assays. Transformation-induced foci were stained
with crystal violet (upper). Colonies formed in soft agar (middle) were counted to quantitate transformation activity (bottom). Error bars represent SEM (n = 3). The
SCFFbw7 targeting by Fbw7 knockdown is not sufficient for rodent cell transformation but decreases soft agar growth induced byMCV sT. Fbw7 knockdown level
was documented in Figure S6.
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SCFFbw7 Complex Targeting by MCV sTcellular conditions. sT targeting of SCFFbw7 can be expected to
perpetuate phosphorylated forms of LT that would otherwise
be marked for rapid turnover. This is functionally reminiscent of
SV40 LT, which interacts with Fbw7 to competitively interfere
with substrate turnover (Welcker and Clurman, 2005) to achieve
similar molecular end results. Other viral proteins, including HPV
E7 (Oh et al., 2004), KSHV vIRF3 (LANA2) (Baresova et al., 2012),
EBV EBNA3C (Knight et al., 2005), HPV E2 (Bellanger et al.,
2010), and adenovirus E1A (Isobe et al., 2009), inhibit SCFFbw7
or related target F box protein complexes, suggesting that this
is a common theme among persistent DNA viral infections.
PP2A targeting is another common feature of polyomavirus
early proteins (Campbell et al., 1995; Pallas et al., 1990; Sontag
et al., 1993) and is critical in defined gene transformation of hu-
man cells using SV40 early proteins (Hahn et al., 1999, 2002).
PP2A actually represents a large class of protein phosphatases,
comprising hundreds of different phosphatase holoenzymes that
use different combinations of PP2AA, B, andC subunits to target
substrate for dephosphorylation. MCV retains PP2A-interacting
domains, but these domains are predicted to be distinct from
the region targeting SCFFbw7. The LSD, required for MCV sT to
transform cells, is on the opposite molecular surface to the
PP2A-docking domain in MCV sT (Figure 2; Movie S1). This
loop is absent from SV40 sT, potentially explaining the inability
of SV40 sT to synergistically promote MCV LT-mediated replica-
tion (Figure 2; Movie S1).
MCC is a dead end for the MCV life cycle because the clonally
integrated virus is no longer capable of producing infectious
virions from tumor cells. MCV targeting of SCFFbw7 through the
MCV sT LSD appears to be a key feature in the normal viral lifeCell Hoscycle that allows the virus to persist and replicate as a harmless
viral skin infection (Tolstov et al., 2011). Under conditions in
which MCV initiates human tumor cell transformation, how-
ever, sT LSD-mediated targeting of viral and cellular oncopro-
teins may contribute to promotion of an aggressive human
malignancy.
EXPERIMENTAL PROCEDURES
Plasmids
Codon-optimized, commercially synthesized MCV LT and sT antigen
sequences were cloned into pcDNA6/V5/His vector (Invitrogen) with a modi-
fied multiple cloning site (MCS). All LT and sT constructs used are untagged.
HA-Fbw7 and Flag-cMyc (Yada et al., 2004) plasmids were kindly provided
by Dr. Nakayama (Kyushu University, Japan). See also the Supplemental
Experimental Procedures.
Cell Lines
293 or U2OS cells were cultured in DMEM with 10% fetal bovine serum (FBS)
from Sigma-Aldrich. MCV-positive MCC cell line MKL-2 was cultured in RPMI
with 10% FBS. HCT116 cells (hCDC4+/+, hCDC4+/, hCDC4/), kindly
provided by Dr. Bert Vogelstein and obtained from Johns Hopkins University
Genetic Resources Core Facility, were grown in McCoy’s 5A medium with
10% FBS. Rat-1 cells and NIH 3T3 cells were maintained in DMEM with 5%
FBS or 10% calf serum, respectively.
MCV Origin Replication Assay
The MCV replication origin assay was described previously (Feng et al., 2011;
Kwun et al., 2009). Briefly, 293 cells were transfected with T antigen expression
vector (LT/sT, 0.3mg), pMCV-Ori339(97) (0.3mg) by Lipofectamine 2000 (Invitro-
gen) in 12-well plates. Forty-eight hours after transfection, episomal DNA was
collected by salt precipitation. DNA was double digested with BamHI and
DpnI, then subjected to Southern hybridization or quantitative real-time PCR.t & Microbe 14, 125–135, August 14, 2013 ª2013 Elsevier Inc. 133
Cell Host & Microbe
SCFFbw7 Complex Targeting by MCV sTStructural Modeling
The model of MCV sT structure was generated using the I-TASSER server
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/) based on SV40 sT homo-
log structures (PDBs 2PF4 and 2PKG). The figures were generated using
PyMOL (http://www.pymol.org/).
Quantitative Real-Time RT-PCR Analysis
293 cells were transfected with LT or sT expression (0.3 mg) constructs, and
total RNA was isolated 2 days after transfection using TRIzol reagent
(Invitrogen). Quantitative real-time PCR was carried out with total RNA
(0.1 mg) and iScript One-Step RT-PCR Kit (Bio-Rad) using a SmartCycler
(Cepheid) according to the manufacturer’s protocol. Primer sequences used
for LT and GAPDH cDNA detection are described in Table S1.
IP and Immunoblotting
Cells were lysed in IP buffer (Tris-HCl [pH 7.4], 150 mMNaCl, 1% or 2% Triton
X-100) freshly supplemented with protease inhibitor cocktail (Roche), 1 mM
PMSF, 5 mM NaF, and 2.5 mM NaVO3. Lysates were incubated with specific
antibody and followed by immunoblotting to detect interacting proteins. All im-
munoblottings were performed with nonclarified whole-cell lysates. See also
Supplemental Experimental Procedures.
Lentiviral/Retroviral Infection for Small Hairpin RNA Knockdown
Small hairpin RNAs (shRNAs) targeting Fbw7 were designed (Table S1) and
cloned into lentiviral vector pLKO.1 (Addgene) using AgeI and EcoRI. A control
shRNA construct was obtained fromAddgene (1864). shRNA-transfected cells
were selected with puromycin (2 mg/ml) for 4 days after infection. See also
Supplemental Experimental Procedures.
Soft Agar Colony-Formation Assay
Rat-1 stably expressing sT antigens were seeded over a 0.6% agar layer in
6-well plate (2.53 104 cells/well) and grown for 3 weeks. Colonies were photo-
graphed and counted after 0.05% crystal violet staining as described previ-
ously (Shuda et al., 2011). All experiments were performed in triplicate.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, one table, and one movie and can be found with this article online
at http://dx.doi.org/10.1016/j.chom.2013.06.008.
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